SCHEMBL3828768

SCHEMBL3828768

CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(Nc4ncccc4-c4cc(NC5CC5)ncn4)c3)cc2C(F)(F)F)CC1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HCK P08631 4/20 0.58
NR2C2 P49116 4/20 0.58
CSF1R P07333 1/20 0.54
KIT P10721 1/20 0.54
EGFR P00533 1/20 0.54
BRAF P15056 1/20 0.54
MAPK1 P28482 1/20 0.54
HTT P42858 1/20 0.54
ATM Q13315 1/20 0.54
MAP3K7 O43318 1/20 0.54
FES P07332 1/20 0.54
FER P16591 1/20 0.54
GCK P35557 1/20 0.54
MAP4K2 Q12851 1/20 0.54
MAPK14 Q16539 1/20 0.54
ABL1 P00519 1/20 0.54
LYN P07948 1/20 0.54
BCR P11274 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3830805 0.91 NR2C2 (0.58) HCKNR2C2EGFRBRAFMAP3K7
SCHEMBL13897932 0.91 HCK (0.48) HCKNR2C2EGFRBRAFMAPK1
SCHEMBL3827617 0.89 HTT (0.59) HCKNR2C2EGFRBRAFMAPK1
SCHEMBL3823189 0.85 BRAF (0.64) BRAFMAPK14ABL1
SCHEMBL1826484 0.85 NR2C2 (0.58) HCKNR2C2EGFRBRAFMAPK1
SCHEMBL3830316 0.84 KIT (0.64) CSF1RKITEGFRBRAFABL1
SCHEMBL3234828 0.82 NR2C2 (0.59) HCKNR2C2EGFRBRAFMAPK1
SCHEMBL13897939 0.82 NR2C2 (0.48) HCKNR2C2EGFRBRAFMAPK1
SCHEMBL3824880 0.82 KDR (0.74) HCKCSF1RBRAFMAPK14LYN
SCHEMBL3826272 0.80 KDR (0.74) HCKCSF1RBRAFMAPK14LYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101421262-A Compounds and compositions as protein kinase inhibitors IRM LLC (VG) 2009-04-29 CN claimed
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-03-12 US claimed
EP-1981870-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-10-22 EP claimed
WO-2007092531-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-08-16 WO claimed
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-03-12 US disclosed
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-03-12 US disclosed
EP-1981870-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-10-22 EP disclosed
WO-2007092531-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-08-16 WO disclosed
WO-2007092531-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS SRC, BMX, FYN HCK 107/4885NR2C2 974/4885CSF1R 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.